{
    "ticker": "OTLK",
    "name": "Outlook Therapeutics, Inc.",
    "description": "Outlook Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat retinal diseases. Founded in 2010, the company is dedicated to addressing unmet medical needs in the ophthalmology sector, particularly for patients suffering from serious eye conditions such as wet age-related macular degeneration (AMD) and diabetic macular edema (DME). Outlook Therapeutics is advancing its lead product candidate, ONS-5010, an injectable formulation of bevacizumab for the treatment of wet AMD. The company is committed to innovation and improving patient outcomes through rigorous clinical development and regulatory processes. By leveraging its proprietary technology platform and extensive research capabilities, Outlook Therapeutics aims to provide effective treatment options that enhance the quality of life for patients. The company is also focused on expanding its pipeline and exploring new therapeutic areas within ophthalmology, with the goal of becoming a leader in the field. As it continues to progress through clinical trials, Outlook Therapeutics seeks to establish partnerships that can facilitate the commercialization of its products and maximize its impact on the healthcare community.",
    "industry": [
        "Biopharmaceutical",
        "Ophthalmology"
    ],
    "headquarters": "Bridgewater, New Jersey, USA",
    "founded": "2010",
    "website": "https://www.outlooktherapeutics.com",
    "ceo": "Michael E. Ehlers",
    "social_media": {
        "twitter": "https://twitter.com/OutlookThera",
        "linkedin": "https://www.linkedin.com/company/outlook-therapeutics"
    },
    "investor_relations": "https://investors.outlooktherapeutics.com",
    "key_executives": [
        {
            "name": "Michael E. Ehlers",
            "position": "CEO"
        },
        {
            "name": "John W. McGowan",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "ONS-5010"
            ]
        }
    ],
    "seo": {
        "meta_title": "Outlook Therapeutics, Inc. | Advancing Ophthalmology Treatments",
        "meta_description": "Explore Outlook Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for retinal diseases. Learn about our lead product, ONS-5010, and our commitment to improving patient outcomes.",
        "keywords": [
            "Outlook Therapeutics",
            "Retinal Diseases",
            "Biopharmaceutical",
            "ONS-5010",
            "Ophthalmology",
            "Wet AMD",
            "Diabetic Macular Edema"
        ]
    },
    "faq": [
        {
            "question": "What is Outlook Therapeutics known for?",
            "answer": "Outlook Therapeutics is known for developing novel therapeutics for retinal diseases, particularly wet age-related macular degeneration."
        },
        {
            "question": "Who is the CEO of Outlook Therapeutics?",
            "answer": "Michael E. Ehlers is the CEO of Outlook Therapeutics, Inc."
        },
        {
            "question": "Where is Outlook Therapeutics headquartered?",
            "answer": "Outlook Therapeutics is headquartered in Bridgewater, New Jersey, USA."
        },
        {
            "question": "What is ONS-5010?",
            "answer": "ONS-5010 is Outlook Therapeutics' lead product candidate, an injectable formulation of bevacizumab for treating wet AMD."
        },
        {
            "question": "When was Outlook Therapeutics founded?",
            "answer": "Outlook Therapeutics was founded in 2010."
        }
    ],
    "competitors": [
        "REGN",
        "BMY",
        "RGEN"
    ],
    "related_stocks": [
        "AMGN",
        "VRTX",
        "GILD",
        "ABBV"
    ]
}